EDAP and Telix announce collaboration on prostate cancer treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
May 14, 2026 7:30 AM EDT, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas May 14, 2026 EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (Telix) to explore joint clinical research activities and physician education focused on the combination of EDAPs Focal One Robotic HIFU and Telixs PSMA PET imaging products in the management of prostate cancer.
The initial area of investigational focus is expected to study the combination of PSMA PET diagnostic imaging scans within the Focal One HIFU treatment workflow to optimize treatment planning, deliver a precise, image-guided... More
